References
- Kieck MJ. Medical complications in methadone patients. Ann NY Acad Sci 1978,311: 110–34
- Ravi NV, Maany I, Burke TO, et al. Detoxification with phenobarbital of alprazolamdependent polysubstance abusers. J Subst Abuse Treat 1990; 7(l): 55–8
- Kolar AF, Brown BS, Weddington WW, et al. A treatment crisis: cocaine use by clients in methadone maintenance programs. J Subst Abuse Treat 1990; 7(2): 101–7
- Condelli WS, Fairbank JA, Dennis ML, et al. Cocaine use by clients in methadone programs: significance, scope, and behavioral interventions. J Subst Abuse Treat 1991; 8(4): 203–12
- Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. JAMA 1965; 193(8): 80–4
- Jafife JH, Martin WK. Opioid analgesics and antagonists. In: Gilman AG, Rail TW, Nies AS, et al, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. Elmsford, NY: Pergamon Press, 1990: 509
- Drugs used for treatment of narcotic addicts (21 CFR291). Federal Register. March 27, 1989: 54: 1253
- Finnegan LP. Treatment issues for opioid-dependent women during the perinatal period. J Psychoactive Drugs 1991; 23(2): 191–201
- Finnegan LP, Hagan T, Kaltenbach KA. Scientific foundation of clinical practice: opiate use in pregnant women. Bull NY Acad Med 1991; 67(3): 223–39
- Payte JT, Khuri ET. Principles of methadone dose determination. In: State methadone treatment guidelines. Rockville, MD: Center for Substance Abuse Treatment, 1993: 48 (Treatment improvement protocol [TIP] series, No. 1)
- Cooper JR. Methadone treatment and acquired immunodeficiency syndrome. JAMA 1989; 262(12): 1664–8
- Batki SL. Treatment of intravenous drug users with AIDS: the role of methadone maintenance. J Psychoactive Drugs 1988; 20(2): 213–6
- Novick DM, Joseph H, Croxson TS, et al. Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Arch Intern Med 1990; 150(1): 97–9
- Selwyn PA. Issues in the clinical management of intravenous drug users with HIV infection. AIDS 1989; 3(Suppl 1): S201–8
- Khantzian EJ, Treece C. DSM-III psychiatric diagnosis of narcotic addicts: recent findings. Arch Gen Psychiatry 1985: 42(11): 1067–71
- Woody GE, O'Brien CP, Rickels K. Depression and anxiety in heroin addicts: a placebo-controlled study of doxepin in combination with methadone. Am J Psychiatry 1975: 132(4): 447–50
- Fultz JM, Senay EC. Guidelines for the management of hospitalized narcotic addicts. Ann Intern Med 1975; 82(6): 815–8
- Tong TG, Pond SM, Kreek MJ, et al. Phenytoin-induced methadone withdrawal. Ann Intern Med 1981; 94(3): 349–51
- Holmes VF. Rifampin-induced methadone withdrawal in AIDS. (Letter) J Clin Psycho-pharmacol 1990; 10(6): 443–4
- Payte, Khuri,10” p 53
- Saxon AJ, Whittaker S, Hawker CS. Valproic acid, unlike other anticonvulsants, has no effect on methadone metabolism: two cases. J Clin Psychiatry 1989; 50(6): 228–9
- Zweben JE, Payte JT. Methadone maintenance in the treatment of opioid dependence: a current perspective. West J Med 1990: 152(5): 588–99
- Ball JC, Ross A. The effectiveness of methadone maintenance treatment: patients, programs, services, and outcome. New York: Springer-Verlag, 1991: 204–5
- Ling W, Wesson D. Drugs of abuse: opiates. West J Med 1990; 152(5): 565–72
- Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978; 35(4): 501–16
- Mello NK, Mendelson JH. Buprenorphine suppresses heroin use by heroin addicts. Science 1980; 207(4431): 657–9
- Rosen MI, Kosten TR. Buprenorphine: beyond methadone? Hosp Community Psychiatry 1991; 42(4): 347–9